Skip to main content
. Author manuscript; available in PMC: 2014 Mar 1.
Published in final edited form as: Eur J Neurosci. 2013 Jan 3;37(6):957–963. doi: 10.1111/ejn.12101

Table 1.

Sleep % in OxR2-siRNA and ctrl-siRNA treated rats.

OxR2-siRNA (N=7) Ctrl-siRNA (N=7)
Period (12 hr) Mean (± SEM) % time spent in Mean (± SEM) % time spent in
Wakefulness NREMS REMS Wakefulness NREMS REMS
Dark 0 68.7±1.4 27.2±1.0 4.0±0.5 62.3±2.6 33.2+2.2 4.5+0.5
Dark 1 64.6±2.6 29.4±2.2 6.0±0.9 * 61.7±2.6 32.9+2.2 5.0+0.5
Dark 2 62.3±2.6 25.9±2.0 6.1±0.7 * 62.6±3.6 32.2+2.9 4.9+0.7
Dark 3 65.2±2.3 29.5±1.5 5.2±1.0
Dark 4 66.9±3.4 28.8±2.7 4.3±0.8
Light0 30.7±2.8 60.2±2.5 9.2±0.7 29.8±3.3 62.0±3.7 8.2±0.5
Light 1 28.2±2.1 60.3±1.7 11.6±0.8 34.1±3.8 58.2±3.9 7.4±0.9
Light 2 29.1 ±1.2 60.0±1.0 10.9±1.2 32.6±2.5 59.1±2.8 7.9±0.7
Light 3 30.4±1.4 60.8±1.1 8.8±0.4
Light 4 30.8±1.3 60.9±0.6 8.3±0.6

Percentage of REM sleep increases on dark periods 1 and 2 in animals treated with OxR2 siRNA. Dark= 7 PM to 7 AM; Light = 7 AM to 7 PM; Dark 0 or Light 0 = Pre-injection dark or light period. Dark 1-4 = Post-injection dark periods; Light 1-4 = post-injection light periods;

*

= P<0.05 versus Dark 0 (Dunnett’s test).